Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 148

Sort by

Sort Order Select

Journal Articles

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Shira Orr, PhD, Marzia Capelletti, PhD MBBS, Haider Ghiasuddin, Dina Stroopinsky, PhD, Jessica Liegel, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Adam Morin, Robin M. Joyce, MD, Salvia Jain, MD, Jon E. Arnason, MD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 392.

https://doi.org/10.1182/blood-2019-124768

Published: 2019

Journal Articles

Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation

Karan R. Kathuria, Binbin Chen, PhD, Michael S. Khodadoust, MD PhD, Niclas Olsson, PhD, Mark M Davis, PhD, Joshua E Elias, PhD, Ronald Levy, MD, Russ B. Altman, MD PhD, Arash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 84.

https://doi.org/10.1182/blood-2019-129334

Published: 2019

Journal Articles

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

Marzia Capelletti, PhD MMSc, Jessica Liegel, MD, Maria Themeli, MD PhD, Tuna Mutis, Dina Stroopinsky, PhD, Shira Orr, PhD, Daniela Torres, Adam Morin, Gertrude Gunset, BA, Haider Ghiasuddin, Maryam Rahimian, MD, Myrna Nahas, MD, Lina Bisharat, Shufen Meng, MD, Nikhil C. Munshi, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, Michel Sadelain, MD PhD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 3227.

https://doi.org/10.1182/blood-2019-124944

Published: 2019

Journal Articles

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Dina Stroopinsky, PhD, Jessica Liegel, MD, Kathleen M. Mahoney, MD PhD, Jacalyn Rosenblatt, MD, Benjamin L. Ebert, MD PhD, Richard M. Stone, MD, Maryam Rahimian, MD, Myrna Nahas, MD, Shira Orr, PhD, Marzia Capelletti, PhD MMSc, Matthew Weinstock, MD, Salvia Jain, MD, Lina Bisharat, MA, Haider Ghiasuddin, BA, Adam Morin, BA, Donald Kufe, MD, Gordon J Freeman, PhD, David E. Avigan, MD

Blood (2018) 132 (Supplement 1): 1446.

https://doi.org/10.1182/blood-2018-99-120259

Published: 2018

Journal Articles

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 59.

https://doi.org/10.1182/blood-2018-99-116828

Published: 2018

Journal Articles

A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review

Nadia Carenina Nunes Cavalcante Parr, MD, Muhammad Junaid Tariq, MD, Muhammad Usman, MD, Muhammad Asad Fraz, MD, Ali Younas Khan, MD, Sharoon Samuel, MBBS, Awais Ijaz, MD, Malik Qistas Ahmad, MD MBBS, Muhammad Jahanzeb Khalil, MD, Muhammad Yasir, MD, Saher Nasir Amin, MD, Ahmad Safdar, Abdul Rafae, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5635.

https://doi.org/10.1182/blood-2018-99-115922

Published: 2018

Journal Articles

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Jooeun Bae, PhD, Parayath Neha, Mansoor Amiji, Nikhil Munshi, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2018-99-117292

Published: 2018

Journal Articles

Introduction to a review series on emerging immunotherapies for hematologic diseases

Sophie Paczesny, Steven Z. Pavletic, Catherine M. Bollard

Blood (2018) 131 (24): 2617–2620.

https://doi.org/10.1182/blood-2018-04-840793

Published: 2018

Journal Articles

Vaccine therapy in hematologic malignancies

David Avigan, Jacalyn Rosenblatt

Blood (2018) 131 (24): 2640–2650.

https://doi.org/10.1182/blood-2017-11-785873

Published: 2018

Journal Articles

Integration of Whole Exome and RNA Sequencing Identifies Neoepitope Vaccine Candidates in >90 Percent of Follicular Lymphoma Patients

Cody Ramirez, BS, Kilannin Krysiak, PhD, Felicia Gomez, PhD, Susanna Kiwala, Christopher A. Miller, PhD, Katie Campbell, Jasreet Hundal, Jason Walker, Malachi Griffith, PhD, Obi Griffith, Todd A. Fehniger, MDPhD

Blood (2017) 130 (Supplement 1): 114.

https://doi.org/10.1182/blood.V130.Suppl_1.114.114

Published: 2017

Journal Articles

Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma

Jooeun Bae, PhD, Derin Keskin, PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Nikhil Munshi, MD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 1867.

https://doi.org/10.1182/blood.V130.Suppl_1.1867.1867

Published: 2017

Journal Articles

Dendritic Cell Production from Allogeneic Donor Cd34+ Stem Cells and Mononuclear Cells; Cancer Vaccine

Ali Unal, Ayse Birekul, Mehmet Cagri Unal, Esen Karakus, Yavuz Köker, Yusuf Ozkul, Faruk Metin Comu

Blood (2016) 128 (22): 5723.

https://doi.org/10.1182/blood.V128.22.5723.5723

Published: 2016

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

Journal Articles

Intratumoral Administration of the Immunotherapeutic Combination Anti-ctla4, Anti-cd137 and Anti-ox40: Comparison to Systemic Administration, Peri-Draining Lymph Node Injection, and Cellular Vaccine in a Mouse Lymphoma Model

Jonathan P. O. Hebb, FRCPC, MD MSC, Adriane Mosley, BSc, Felipe Vences Catalan, Peter Ellmark, Per Norlen, Dean W Felsher, MD PhD

Blood (2016) 128 (22): 4172.

https://doi.org/10.1182/blood.V128.22.4172.4172

Published: 2016

Journal Articles

Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes Are Enhanced By HDAC6 Inhibitor ACY241

Jooeun Bae, PhD, Matthew Ho, Brandon Nguyen, Arghya Ray, PhD, Dharminder Chauhan, PhD, Teru Hideshima, MD PhD, Nikhil Munshi, MD, Kenneth C Anderson, MD

Blood (2016) 128 (22): 2143.

https://doi.org/10.1182/blood.V128.22.2143.2143

Published: 2016

Journal Articles

Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)

Ajay K Nooka, MD MPH, Michael Wang, MD, Andrew J. Yee, MD, Sheeba K. Thomas, MD, Elizabeth K. O'Donnell, MD, Jatin J. Shah, MD, Jonathan L. Kaufman, MD, Doris Peterkin, MBA, Sagar Lonial, MD FACP, Paul G. Richardson, MD, Noopur Raje, MD

Blood (2016) 128 (22): 2124.

https://doi.org/10.1182/blood.V128.22.2124.2124

Published: 2016

Journal Articles

Identification and Validation of HLA-A24 XBP1 us , XBP1 sp , CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers

Jooeun Bae, PhD, Brandon Nguyen, Matthew Ho, Yan Song, PhD, Noopur Raje, MD, Paul G. Richardson, MD, Teru Hideshima, MD PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 5689.

https://doi.org/10.1182/blood.V128.22.5689.5689

Published: 2016

Journal Articles

A Systematic Approach to Providing Safe Quality Care for Patients Receiving Engineered, Non-Stem Cell Therapies

Sarah Nikiforow, MD PhD, Sarah Winawer-Wetzel, MBA, Sheila Phicil, MPH, Kurt Lowery, BS, Brett Glotzbecker, MD, Marsha Clements, MSN/ED, RN, Robert Mersereau, MS, Olive Sturtevant, MT, MHP, Ilene Galinsky, MSN, ANPc, William J Savage, MD, Edwin P. Alyea, III, MD, Robert J. Soiffer, MD, Craig Bunnell, MD MPH, MBA, Amy Emmert, MSc PH

Blood (2016) 128 (22): 2371.

https://doi.org/10.1182/blood.V128.22.2371.2371

Published: 2016

Journal Articles

DSP-7888, a Novel Cocktail Design of WT1 Peptide Vaccine, and Its Combinational Immunotherapy with Immune Checkpoint-Blocking Antibody Against PD-1

Masashi Goto, PhD, Megumi Nakamura, PhD, Natsuko Suginobe, MS, Hideo Takasu, PhD, Yosuke Takanashi, MS, Hitoshi Ban, PhD, Chiang J Li, MD

Blood (2016) 128 (22): 4715.

https://doi.org/10.1182/blood.V128.22.4715.4715

Published: 2016

Journal Articles

A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma

Rebecca Karp Leaf, MD, Dina Stroopinsky, PhD, Athalia Rachel Pyzer, MD, Ada M. Kruisbeek, PhD, Sandra Van Wetering, PhD, Abigail J. Washington, BA, Leandra Cole, BA, Myrna R. Nahas, MD, Salvia Jain, MD, Arie Apel, MD, Jon Arnason, MD, Ayad Hamdan, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2016) 128 (22): 4484.

https://doi.org/10.1182/blood.V128.22.4484.4484

Published: 2016

NARROW

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Introduction to a review series on emerging immunotherapies for hematologic diseases

Vaccine therapy in hematologic malignancies

Integration of Whole Exome and RNA Sequencing Identifies Neoepitope Vaccine Candidates in >90 Percent of Follicular Lymphoma Patients

Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma

Dendritic Cell Production from Allogeneic Donor Cd34+ Stem Cells and Mononuclear Cells; Cancer Vaccine

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Intratumoral Administration of the Immunotherapeutic Combination Anti-ctla4, Anti-cd137 and Anti-ox40: Comparison to Systemic Administration, Peri-Draining Lymph Node Injection, and Cellular Vaccine in a Mouse Lymphoma Model

Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes Are Enhanced By HDAC6 Inhibitor ACY241

Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)

Identification and Validation of HLA-A24 XBP1 us , XBP1 sp , CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers

A Systematic Approach to Providing Safe Quality Care for Patients Receiving Engineered, Non-Stem Cell Therapies

DSP-7888, a Novel Cocktail Design of WT1 Peptide Vaccine, and Its Combinational Immunotherapy with Immune Checkpoint-Blocking Antibody Against PD-1

A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only